% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pagliuca:299008,
      author       = {S. Pagliuca and F. Malard and J. E. Mooyaart and M.
                      Daskalakis and L. Gabellier and I. Yakoub-Agha and R. Ram
                      and C. Besley and E. Forcade and V. Vucinic and L. L. Corral
                      and J. Vydra and B. von Tresckow$^*$ and P. Amat and P.
                      Amrolia and P. Vandenberghe and F. Stölzel and S. Sica and
                      M. T. Rubio and J. D. Hoogenboom and V. Ortiz-Maldonado and
                      A. Nagler and J. Kuball and C. Chabannon and A. Ruggeri},
      title        = {{T}he landscape of immune monitoring in {CAR}-{T} cell
                      therapy: {A} comprehensive review and survey study by the
                      {C}ellular {T}herapy and {I}mmunobiology {W}orking {P}arty
                      of the {EBMT}.},
      journal      = {Blood reviews},
      volume       = {71},
      issn         = {0268-960X},
      address      = {Burlington, Mass.},
      publisher    = {Harcourt},
      reportid     = {DKFZ-2025-00418},
      pages        = {101272},
      year         = {2025},
      note         = {Volume 71, May 2025, 101272},
      abstract     = {Immune monitoring of cell therapies is a complex and
                      evolving topic, particularly in the rapid expanding field of
                      chimeric antigen receptor T (CAR-T) cell applications.
                      Defining essential, recommended, and optional immune
                      monitoring data post-CAR-T cell infusion is crucial to
                      improve patient outcomes and inform post-treatment
                      decisions. To address this gap, we conducted a survey-based
                      study across centers affiliated with the European Society
                      for Blood and Marrow Transplantation (EBMT), focusing on
                      patients treated with European Medicines Agency
                      (EMA)-approved CAR-T products. Building on a thorough review
                      of the literature, we mapped the current landscape of immune
                      monitoring practices and assessed their impact on clinical
                      management. By defining the state of the art in the field,
                      this work marks an initial step towards a structured
                      harmonization process potentially able to enhance the
                      management and outcomes of patients undergoing these immune
                      cell therapies.},
      subtyp        = {Review Article},
      keywords     = {B cell aplasia (Other) / CAR-T cell expansion (Other) /
                      CAR-T cells (Other) / CRS (Other) / ICANS (Other) / Immune
                      monitoring (Other) / Immune reconstitution (Other) /
                      Lentiviral integration (Other) / Transduction (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39986989},
      doi          = {10.1016/j.blre.2025.101272},
      url          = {https://inrepo02.dkfz.de/record/299008},
}